爱多克萨班抗血栓治疗心房动和稳定冠状动脉疾病的治疗方法
Min Soo Cho1, Do-Yoon Kang1, Jung-Min Ahn1
1From the Department of Cardiology (M.S.C., D.-Y.K., J.-M.A., S.-J.P., D.-W.P., G.-B.N.) and the Division of Biostatics (S.-C.Y.), Asan Medical Center, University of Ulsan College of Medicine, the Department of Cardiology, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea (Y.-S.O.), the Department of Cardiology, Veterans Health Service Medical Center (C.H.L.), the Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital (E.-K.C.), the Division of Cardiology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine (C.H.K.), the Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (K.-M.P.), the Department of Cardiology, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical College (E.-S.J.), and the Division of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, Catholic University of Korea (O.K.), Seoul, the Cardiovascular Center, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam (J.H.L.), the Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan (G.-M.P.), the Department of Cardiology, Soon Chun Hyang University Hospital Bucheon, Bucheon (H.O.C.), the Department of Cardiology, Hallym University Medical Center, Anyang (K.-H.P.), the Department of Cardiology, Keimyung University Dongsan Hospital, Daegu (J.H.), the Department of Cardiology, St. Vincent's Hospital, College of Medicine, Catholic University of Korea, Suwon (K.-D.Y.), the Department of Cardiology, Dong-A University Hospital, Dong-A University College of Medicine (Y.-R.C.), and the Department of Cardiology, Haeundae Paik Hospital, Inje University College of Medicine (K.-H.K.), Busan, the Department of Cardiology, Dongguk University Ilsan Hospital, Goyang (J.H.K.), and the Department of Cardiology, Pusan National University Yangsan Hospital, Pusan National University of Medicine, Yangsan (K.W.H.) - all in South Korea.
与双重抗血栓治疗相比,埃多克萨班单一治疗显著降低了心房动和稳定冠状动脉疾病患者主要不良事件的风险. 这一策略还降低了重大出血事件的发生率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 对心房动和稳定冠状动脉疾病患者的长期抗血栓治疗策略缺乏强大的随机试验数据.
- 临床指南始终建议抗血栓治疗,但最佳的长期方法需要进一步调查.
研究的目的:
- 在患有心房动和稳定冠状动脉疾病的患者中,比较EDOXABAN单一治疗与双重抗血栓治疗的疗效和安全性.
- 评估该患者群体中复合不良事件的长期风险,包括死亡,缺血事件和出血.
主要方法:
- 一个多中心的,开放的标签,评委蒙面的随机试验,涉及1040名患者.
- 患有心房动和稳定的冠状动脉疾病的患者随机分配到接受edoxaban单一疗法或双重抗血栓治疗 (edoxaban加一种单一抗血小板剂).
- 主要结局是12个月死亡,心肌梗塞,中风,全身栓塞,非计划的紧急再血管化和重大或临床相关的非重大出血的组合.
主要成果:
- 与双重抗血栓治疗相比,埃多克萨班单一治疗导致主要复合结局发生率显著降低 (6.8%与16.2%相比;危险比,0.44;P<0.001).
- 大型出血或临床相关的非大型出血在埃多克萨班单疗时发生的频率较低 (4.7%对14.2%;危险比率0.34).
- 在这两组中,主要缺血事件的累积发病率是相似的.
结论:
- 与双重抗血栓治疗相比,埃多克萨班单一治疗与心房动和稳定冠状动脉疾病患者的重大不良事件和出血风险降低有关.
- 这项研究提供了重要的证据,支持埃多克萨班单一治疗作为这种患者队列的潜在更安全和更有效的长期抗血栓治疗策略.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers


